ArticleFrontiers in oncology2025
GNG7 as a tumor-suppressor gene in lung adenocarcinoma: implications for prognosis and immune-based therapies.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Characterization and pathogenic mechanisms of aFrontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Lung adenocarcinoma (LUAD) is among the most prevalent and lethal forms of cancer worldwide, largely due to the lack of early symptoms and frequent late-stage diagnosis. G protein γ subunit 7 (GNG7) has been implicated in the regulation of cell proliferation, apoptosis, and migration across various cancers. However, its immunological role in LUAD progression remains poorly understood. Methods: We analyzed The Cancer Genome Atlas (TCGA) database to assess the relationship between GNG7 expression and clinical outcomes in LUAD. Immune cell infiltration and immune-related gene expression were evaluated in association with GNG7 levels. In vitro functional assays, including proliferation, migration, invasion, and apoptosis assays, were performed following GNG7 overexpression. A prognostic model was constructed based on immune-related genes regulated by GNG7 and validated using the GSE31210 and IMvigor210 cohorts. Results: Low GNG7 expression was associated with enhanced tumor growth and poor prognosis in LUAD patients. GNG7 expression correlated significantly with immune cell infiltration and key immune regulatory markers. In vitro, GNG7 overexpression suppressed LUAD cell proliferation, migration, and invasion, while promoting apoptosis. The developed GNG7-related immune gene prognostic model effectively predicted both patient prognosis and immunotherapy response. Discussion: Our findings highlight the critical role of GNG7 in LUAD progression and its modulation of the tumor immune microenvironment. GNG7 shows promise as a prognostic biomarker and potential therapeutic target for immune-based LUAD treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.